Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Tobacco Use Disorder 1Stomach Neoplasms 1Mouth Neoplasms 1Lichen Planus 1Leukokeratosis, Hereditary Mucosal 1Fanconi Anemia 1Erythroplasia 1

Interventions

Oxaliplatin 29Fluorouracil 23Capecitabine 19pembrolizumab 17Nivolumab 17Leucovorin 16Docetaxel 10Paclitaxel 9Drug Therapy 9Cisplatin 9fludarabine 8Trastuzumab 8S 1 (combination) 8Cyclophosphamide 8Specimen Handling 7trastuzumab deruxtecan 6Bevacizumab 6Magnetic Resonance Spectroscopy 5Biopsy 5zolbetuximab 4Irinotecan 4Carboplatin 4zimberelimab 3sintilimab 3olaparib 3fludarabine phosphate 3durvalumab 3atezolizumab 3aldesleukin 3XELOX 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Molecular Diagnostic Techniques × 90 days × Clear all
NCT04600466 2026-04-14

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

The University of Texas Health Science Center at San Antonio

Terminated
129 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡